{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.\n\nComplete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n\nnear Complete Response (nCR): Patients who meet all criteria for CR except a positive immunofixation will be classified as nCR.\n\nVery Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<100mg per 24hours; \\<=5% plasma cells in bone marrow.","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"After 4 months of treatment","title":"Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment","type":"PRIMARY","unitOfMeasure":"participants"}